12-Month clinical data abstract accepted for Poster Presentation at ICS 2019

24 July 2019

We are pleased to announce that the 12-month follow-up data of our clinical study ‘Treatment with a polycaprolactone (PCL)-based bioresorbable urethral bulking agent for mild to moderate stress urinary incontinence (SUI)’ has been accepted for ePoster Presentation (Abstract 122) on Wednesday 4th of September 14:50h (ePoster Station 6) at the upcoming ICS Annual Meeting, 3-6 September 2019 in Gothenburg, Sweden.

ICS 2019, annual meeting, gothenburg, sweden


The study shows that the PCL-based bioresorbable urethral implant treatment is safe and effective for women with mild to moderate SUI, resulting in improvements in both SUI severity and QoL up to 12 months. As the study is ongoing (up-to 2 years follow-up), more data will become available soon.

Please click here to read the full abstract.

Please click here to download the ePoster.